Yes, SKYRIZI can elevate cholesterol levels.
Clinical studies have shown that treatment with SKYRIZI can lead to increases in certain lipid parameters. Specifically, elevations in both total cholesterol and low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol, have been observed.
How SKYRIZI Affects Cholesterol
Observations regarding cholesterol changes with SKYRIZI treatment were noted early in the induction trials (CD-1 and CD-2).
- Initial Assessment: Elevations in lipid parameters were first assessed at 4 weeks after patients began treatment with SKYRIZI.
- Observed Changes: At Week 4, increases from baseline cholesterol levels were observed. Furthermore, these increases were also noted when compared to patients receiving a placebo.
- Stability: The elevated cholesterol levels, specifically total cholesterol and LDL-C, remained stable through Week 12 of treatment.
It is important for healthcare providers to monitor patients' lipid profiles during treatment with SKYRIZI, especially considering these observed changes in cholesterol levels.
